New REDUCE-IT® Data Show VASCEPA®/VAZKEPA® (icosapent ethyl) Reduced STEMI as Well as Other MI Subtypes
-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses --...
-- Late-Breaking Data Show VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27% in Pre-Specified, Post Hoc Analyses --...
VANCOUVER, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased...
MyoVista FDA De Novo Resubmission Expected in Current Fiscal Year Completed IPO in June 2022 with Approximately $6.375M of Gross...
By Stuart Long Cardiac monitoring technology has changed exponentially since a rolled-up newspaper was used as the first stethoscope more...
By Stuart Long, CEO of InfoBionic Improvements in data storage and management, deep learning, artificial intelligence and secure telecommunications have...